ABT : Analysis & Opinions

  1. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  2. There’s Still Room For Dividends In Your Portfolio

    January 7, 2014
    When the Fed decided to begin tapering, it sent shockwaves throughout the dividend stock sector. However, those “shockwaves” ...
  3. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  4. DC Hijinx Cloud Earnings Season - Ahead of Wall Street

    October 16, 2013
    Oh yeah, almost forgot -- earnings season is hitting full throttle this week.
  5. DC Hijinx Cloud Earnings Season - Ahead of Wall Street

    October 16, 2013
    Oh yeah, almost forgot -- earnings season is hitting full throttle this week.
  6. MedTech Industry Stock Update - Sept 2013 - Industry Outlook

    September 10, 2013
    MedTech Industry Stock Update - Sept 2013 - Industry Outlook
  7. Becton Dickinson Already Priced For Excellence

    August 1, 2013
    BD remains a dependable company, but the Street seems to be expecting too much.
  8. Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook

    July 30, 2013
    Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook
  9. Roche Delivering Leverage, But Still Needs Diversification

    July 29, 2013
    If Roche can balance out its sales mix, the long-term value could be quite compelling at present prices.
  10. Earnings Preview: J&J to Report In Line? - Analyst Blog

    July 15, 2013
    We expect Johnson & Johnson (JNJ) to report in line second-quarter 2013 results.
  11. Will Earnings Growth Bottom in Q2? - Earnings Trends

    July 5, 2013
    Will Earnings Growth Bottom in Q2? - Earnings Trends
  12. Will Earnings Growth Bottom in Q2? - Earnings Outlook

    July 5, 2013
    Will Earnings Growth Bottom in Q2? - Earnings Outlook
  13. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  14. Pharma Is Doing All The Pulling For Johnson & Johnson

    April 17, 2013
    Although JNJ reported decent earnings and has some major new drugs lined up - downside risk is definitely still present.
  15. Mead Johnson Nutrition's Valuation Looks Bloated

    February 5, 2013
    Mead Johnson seems overvalued for its above-average growth prospects.
  16. Stock Market News for January 30, 2013 - Market News

    January 30, 2013
    Better-than-expected quarterly results once again guided the S&P 500 and the Dow Jones into the green on Tuesday. Strong ...
  17. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  18. MedTech Industry Stock Outlook - Jan 2013 - Industry Outlook

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  19. Covidien's 1Q Beats, Raises View - Analyst Blog

    January 25, 2013
    Covidien plc. (COV) reported its adjusted earnings per share of $1.10 for the first quarter of fiscal 2013, 4 cents above ...
  20. Stock Market News for January 8, 2013 - Market News

    January 8, 2013
    Investor apprehensions surrounding fourth-quarter earnings dragged benchmarks into negative territory on Monday. Indices ...
  21. Patent Challenge for Auxilium Pharma - Analyst Blog

    January 7, 2013
    Auxilium Pharmaceuticals, Inc. (AUXL) and Xstelos Holdings, Inc. (XTLS) recently received a notice from Upsher-Smith Laboratories, ...
  22. Coronado Amends Ovamed Agreement - Analyst Blog

    January 3, 2013
    Coronado Biosciences (CNDO) recently amended its existing license and supply agreements with Ovamed GmbH. Coronado now has ...
  23. Myriad Alleviates to Outperform - Analyst Blog

    December 21, 2012
    Following a strong first quarter result and an encouraging guidance, we upgrade our recommendation on Myriad Genetics (MYGN), ...
  24. An End to Drug Patent Woes? - Analyst Blog

    December 14, 2012
    The US Supreme Court will soon hear a case which will determine whether "pay-for-delay" agreements between drug manufacturers ...
  25. Myriad Teams Up with Sanofi - Analyst Blog

    December 11, 2012
    Myriad RBM, a wholly-owned subsidiary of molecular diagnostic company Myriad Genetics Inc. (MYGN), has recently collaborated ...
  26. Pharma & Biotech Stock Outlook - Dec 2012 - Zacks Analyst Interviews

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  27. Pharma & Biotech Stock Outlook - Dec 2012 - Industry Outlook

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  28. Abbott's Humira's Label Expanded - Analyst Blog

    November 28, 2012
    Abbott Labs (ABT) recently received approval for yet another indication of Humira (adalimumab). The European Commission approved ...
  29. BASF's Deal For Pronova Shows The Importance Of Good Nutrition

    November 23, 2012
    BASF ties up another high-grade fish oil company in Pronovna, adding to the recent rise in popularity for the fish oil space.
  30. Beat and Raise Quarter for Amgen - Analyst Blog

    October 24, 2012
    Amgen (AMGN) continued its strong performance in 2012 with third quarter earnings coming in at $1.66 per share, 23 cents ...
  31. Abbott Among Healthcare's Biggest Movers on October 18, 2012

    October 18, 2012
    The Nasdaq has decreased 0.3%, the S&P 500 has moved little and the Dow has climbed 0.1% so far today. The healthcare sector ...
  32. Drugs Have Moved J&J On To A New Phase

    October 17, 2012
    J&J is back on a growth track, but the device business needs fixing.
  33. Abbott Reports Encouraging HCV Data - Analyst Blog

    October 16, 2012
    Abbott Laboratories (ABT) recently announced promising data from the phase IIb Aviator trial evaluating the combination of ...
  34. Stock Market News for October 16, 2012 - Market News

    October 16, 2012
    Strong September retail sales data coupled with better-than-expected quarterly results by Citigroup drove the benchmarks ...
  35. NYSE Stocks, Including Abbott, Making Big Moves on October 15, ...

    October 15, 2012
    The market is on the rise so far this morning. The Nasdaq has risen 0.3%; the S&P 500 is trading up 0.3%; and the Dow has ...
  36. Healthcare Stocks, Including Abbott, Making Big Moves on October ...

    October 15, 2012
    The Nasdaq is up 0.3%, the S&P 500 has risen 0.3% and the Dow has climbed 0.3%, marking a bad morning for the market. The ...
  37. New Indication for Abbott's Humira - Analyst Blog

    October 4, 2012
    Abbott Labs (ABT) recently announced that it has received approval for an additional indication of Humira (adalimumab) from ...
  38. Apricus, Takeda Ink Marketing Deal - Analyst Blog

    September 14, 2012
    Apricus Biosciences, Inc. (APRI) and Takeda Pharmaceuticals (TKPYY) recently signed an exclusive licensing agreement to market ...
  39. More Healthy Alternatives To Zimmer

    July 30, 2012
    Zimmer has turned to cost cutting to keep total profit growth moving positively forward, but doesn't appear to have any answers ...
  40. Amgen Beats, Raises Guidance - Analyst Blog

    July 27, 2012
    Amgen (AMGN) continued its strong performance in 2012 with second quarter earnings coming in at $1.82 per share, 31 cents ...
  41. The Week Ahead In Healthcare

    July 24, 2012
    Healthcare stocks continue to outperform this year. However, a lot of this outperformance seems to be coming from lower tax ...
  42. Company News for July 19, 2012 - Corporate Summary

    July 19, 2012
    "    Yahoo! Inc. (NASDAQ:YHOO) reported second quarter earnings per share of $0.27, higher than the Zacks Consensus Estimate ...
  43. Bio-Reference Labs Taking Advantage Of Esoteric Opportunities

    June 22, 2012
    The decision of whether to buy Bio-Reference really comes down to an investor's confidence in the growth prospects for the ...
  44. Vermillion Presents Positive Data - Analyst Blog

    June 18, 2012
    Leading developer of diagnostics tests, Vermillion, Inc. (VRML) reported that it had presented the results for the intended ...
  45. New Lease Agreements for Alexandria - Analyst Blog

    June 8, 2012
    Alexandria Real Estate Equities, Inc. (ARE), a real estate investment trust (REIT), recently entered into long-term agreements ...
  46. Abbott Presents Data on Humira - Analyst Blog

    June 7, 2012
    Abbott Labs (ABT) recently presented phase III data on its blockbuster drug, Humira, from two studies. While ABILITY-2 is ...
  47. BMY Presents Positive Data - Analyst Blog

    June 6, 2012
    Bristol-Myers Squibb Company (BMY) recently presented encouraging data from a late-stage study (AMPLE: n=646), which evaluated ...
  48. ilent Pays A Hefty Price For A Fixer-Upper Diagnostics Company

    May 22, 2012
    Agilent is paying up to get into the increasingly crowded diagnostics market.
  49. Nestle Almost Never On Sale

    April 24, 2012
    Nestle has a well-earned reputation for excellence and the Street has long been happy to pay a premium for that performance. ...
  50. J&J Sticking Together

    April 23, 2012
    There is turnaround potential at J&J as it regains its former glory. The company has decided that operating a diversified ...
  51. Smart Stocks To Rally With

    March 28, 2012
    As the market advances, investing risk naturally increases but seeking out quality companies where you can pay below a reasonable ...
  52. Rallying Large Caps With Strong Sources Of Profitability

    March 12, 2012
    The market rallied to make up for last week's drop.
  53. Medtronic In Recovery Mode

    February 27, 2012
    Medtronic's valuation is very appealing given its leadership position in the medical device industry.
  54. Zimmer Holdings Still Struggling To Grow

    January 31, 2012
    Zimmer is experiencing modest growth, but is struggling to grow as much as companies that offer heart-related medical devices.
  55. Abbott Labs Dividing Its Growth And Income Potential

    January 26, 2012
    With the coming split of operations, Abbott Labs investors will better be able to choose between growth and income.
  56. 2011 - Another Sick Year For Larger Med-Tech

    December 29, 2011
    Larger healthcare companies are still getting sickly returns in the market.
  57. Will Qiagen's Restructuring Address The Real Problems?

    November 30, 2011
    Will Qiagen's Restructuring Address The Real Problems?
  58. Medtronic May Be A Heavyweight, But It Can Still Hit Hard

    November 28, 2011
    Medtronic has gone from over-loved to under-loved, and value investors should take note.
  59. Covidien Delivers Once Again

    November 21, 2011
    Covidien is overlooked and undervalued.
  60. Is Hologic A Coiled Spring?

    November 11, 2011
    Hologic looks cheap on even modest growth recovery expectations.
  61. Should Pfizer Forget R&D Altogether?

    November 2, 2011
    Pfizer has to convince the Street that it can still grow, but the stock is cheap for now.
  62. PerkinElmer Adds High-End Tools To Its Box

    September 13, 2011
    Caliper's rebound comes to an end with a premium take-out by PerkinElmer.
  63. XOMA Rearranges The Deck Chairs One More Time

    September 2, 2011
    XOMA changes management again, but should anybody care?
  64. 4 Companies Swimming In Cash

    September 1, 2011
    Learn more about four companies that have managed impressive operating cash flow amid August's unstable markets.
  65. 5 Bullish Macd Crossovers

    August 17, 2011
    Knowing when trends are about to reverse is tricky business, but the MACD can help.
  66. BD Healthy, But No Great Bargain

    August 9, 2011
    BD is not the cheapest health care name, but it comes with a lot of quality.
  67. The Perpetual Boston Scientific Turnaround Story

    August 4, 2011
    Another quarter brings another hope for better days at BSX.
  68. Drugs Don't Cure All That Ails J&J

    July 20, 2011
    JNJ's performance is mediocre, as are its investment prospects.
  69. More To Merck Than Meets The Eye?

    June 22, 2011
    Merck is set up to exceed low-ball estimates.
  70. Johnson & Johnson Surrenders In Stents

    June 17, 2011
    JNJ makes a tough and surprising, but ultimately wise, decision.
  71. Should Investors Worry If Gen-Probe Doesn't Sell Out?

    June 10, 2011
    Not selling may be the best move Gen-Probe can make for its shareholders.
  72. Medtronic Still Muddling Through

    May 27, 2011
    Medtronic is going nowhere fast, but the quality hasn't left.
  73. Will Nestle Succeed Where Others Have Failed?

    May 26, 2011
    Nestle is making an interesting step into medical pharmaceuticals and diagnostics.
  74. 4 Defensive Stocks To Defend Against A Downturn

    May 25, 2011
    Large, defensive stocks pose minimal risk for the upside potential.
  75. Teva And Cephalon Solve Each Other's Problems

    May 4, 2011
    Teva's acquisition of Cephalon is a logical deal that solves problems for each company.
  76. Hologic Holding The Line

    May 4, 2011
    Hologic lacks exciting growth, but the technology is in place for better growth in the future.
  77. What Becton Dickinson Lacks In Flash, It Makes Up For In Quality

    April 28, 2011
    Becton Dickinson is a great company with improving prospects that is ideal for long-term investors.
  78. 5-Star Healthcare Dividend Stocks

    April 28, 2011
    Healthcare is an increasingly worthwhile destination for dividend shoppers.
  79. Can St. Jude Live Up To Newfound Expectations?

    April 25, 2011
    St. Jude faces something it has rarely seen in the past - high expectations.
  80. Endo Choosing The Less Traveled Path

    April 12, 2011
    Endo makes an unusual move to get into the device space.
  81. The Market's Most Overestimated Stocks

    April 1, 2011
    The market loves a good story stock, but sometimes, the math behind the story doesn't paint a very pretty picture.
  82. Quest Diagnostics Opens Its Wallet One More Time

    March 22, 2011
    Quest shows once again that it is willing to pay for what may become valuable testing technology.
  83. Healthy Dividend-Growth Ideas In Healthcare

    March 16, 2011
    Healthcare is an increasingly worthwhile destination for dividend shoppers.
  84. DexCom Shows Diabetes Still A Growth Industry

    March 9, 2011
    DexCom shows that, although times are tough, people will still adopt better technology.
  85. Can NutriSystem Find A Healthy Size?

    February 28, 2011
    NutriSystem got crushed on bad earnings guidance, but there could be more value here than people realize.
  86. Medtronic's Midlife Crisis

    February 24, 2011
    Medtronic lacks growth, but quality is still in place.
  87. Danaher Hopes To Revive Beckman Coulter

    February 9, 2011
    Learn more about Danaher's expensive, albeit strategic, bid for a leading diagnostics franchise.
  88. Danaher - Wait For Quality To Come Cheap

    February 1, 2011
    Danaher delivers another good year of growth and free cash flow.
  89. A Foursome Of Pharma Earnings Suggests Business Is Still Tough

    January 31, 2011
    There's little growth to excite pharma investors, but there is more value here than some realize.
  90. A Royal Present For Martek Shareholders

    December 23, 2010
    DSM furthers its transition to a food and health-focused chemical company.
  91. Roche Noise May Be A Buyer's Best Friend

    December 22, 2010
    A spate of bad news may have Roche in great value shape.
  92. Big Dividends In Large Caps

    December 17, 2010
    These five stocks pay good dividends and can help balance an otherwise unstable portfolio.
  93. Does Beckman Bow To The Inevitable?

    December 14, 2010
    Beckman is doing right by shareholders if it sells the company.
  94. FDA's Bizarro World - Orexigen Gets Panel Approval!

    December 8, 2010
    In a surprise decision, an FDA panel votes to approve Contrave, Orexigen's new obesity drug.
  95. Medtronic Worth The Wait

    November 24, 2010
    Wall Street is giving no credit to a very well-run franchise.
  96. MELA Sciences' New Device: Will It Be Approved?

    November 19, 2010
    A surprising panel decision raises hopes, but offers no guarantees.
  97. Qiagen Hopes To Ride MDx

    November 11, 2010
    Qiagen doesn't seem to be earning the healthy esteem Wall Street has for the stock.
  98. With Minimal Expectations, Hologic Could Still Surprise

    November 10, 2010
    Hologic is suffering from low expectations, but value investors may have a bargain here.
  99. BDX: A Quality Company And Priced Like It

    November 8, 2010
    Becton, Dickinson is posting sluggish growth, but it's worth a look at the right price.
  100. Vivus Gets An Encouraging “No”

    October 29, 2010
    Vivus gets a big boost of encouragement from a benign FDA rejection.
  101. Boston Scientific Has A Long Road Back

    October 21, 2010
    Boston Scientific is priced to do almost nothing, but that may underestimate the potential of operating improvement.
  102. Roche Needs A Shot Of Adrenalin

    October 18, 2010
    Roche has a lot of great value characteristics, but value will wither in the absence of growth.
  103. Immucor Investors Out For Blood

    October 7, 2010
    This company has the right technology and product mix to succeed, but now it has to show it has the capabilities to match.
  104. Neogen Is No Bad Egg

    September 28, 2010
    Food safety scares bring new attention to a proven performer.
  105. Orexigen Finds A Cautious Partner

    September 3, 2010
    Orexigen gets the going rate for an obesity drug with low expectations.
  106. Medtronic Looks A Little Woozy

    August 26, 2010
    It seems that the expectations for Medtronic are so low that long-term investors have little to fear.
  107. Revealing Four Companies' Earnings Quality

    August 17, 2010
    How to perform a quick quality test to ascertain a company's earnings quality.
  108. Two Under-The-Radar Reports In Med-Tech

    August 3, 2010
    Two lesser-known med-tech companies could turn into very interesting stocks with only small amounts of outperformance.
  109. Stocks To Guard Your Portfolio

    July 1, 2010
    Finding the right stock to reduce volatility is not as exciting, but it is essential to building a lasting portfolio and ...
  110. Can Investors Fatten Up On Weight Loss?

    June 22, 2010
    Obesity is described as a multi-billion dollar crisis in North America, but how can investors profit from the solutions?
  111. ASCO - A Big Deal For Biotechs

    May 27, 2010
    ASCO is a major event for the pharmaceutical and biotech industry, and these stocks could shine in the limelight.
  112. After The Dust Settles

    May 12, 2010
    When the market calms down after the wild price swings and sell-off it's undergoing, there will be opportunities for long-term ...
  113. Shopping Time In Medical Technology?

    May 6, 2010
    Is Medtronic's acquisition of ATS Medical the beginning of another M&A wave in med-tech?
  114. Becton Dickinson More Interesting Than You Think

    May 3, 2010
    Becton Dickinson is often dismissed as "boring" but a diversified cash-generating business with real growth shouldn't be.
  115. Can Boston Scientific Ever Get It Right?

    April 30, 2010
    Boston Scientific has been a perrenial underperformer. Can the company turn it around?
  116. GlaxoSmithKline On Simmer

    April 30, 2010
    Glaxo's earnings look powerful, but is this really a top idea in the pharma sector?
  117. Four Stocks With Low P/Es And Great Dividends

    March 15, 2010
    These four are selling for cheap and paying out big.
  118. Dividend Boosters On The Rise

    March 2, 2010
    If management knows best, these companies could be headed substantially higher.
  119. A Look Back On Deals In 2009

    December 24, 2009
    2009 was an exciting year for mergers, buyouts, industry consolidation plays and hostile takeover attempts.
  120. 4 Companies Raising Earnings Guidance

    October 20, 2009
    Third quarter earning season is off to a good start, as a record number of companies have raised guidance.
  121. 3 Slow-and-Steady Healthcare Stocks

    October 8, 2009
    J&J, Abbot and Baxter are looking robust, despite the ailing economy.
  122. Drug Company Dividends On Steroids

    August 7, 2009
    Here's one more advantage to owning the global pharmaceutical giants.
  123. April Large Cap Losers

    May 4, 2009
    The large cap loser list for April consists of former safe havens that have suffered from investor shifts to sectors that ...
  124. Medical Devices: Cure For Ailing Portfolios?

    February 27, 2009
    Find out how these medical device makers may resuscitate your ailing portfolio.
  125. Invest In The Original S&P 500

    February 18, 2009
    An amazing number of the original companies in the S&P 500 index are still trading. I'll pick out some interesting choices ...
  126. Forseeing 2009's Best Stocks

    January 12, 2009
    Will a "green revolution" be the ticket to 2009's hottest stocks? Only time will tell, but you can get in early by learning ...
  127. Big Predictions For Big Pharma

    January 2, 2009
    As defensive plays, Big Pharma stocks could beat the economic crunch.
  128. Medtronic Sneezes, Investors Feel Sick

    November 24, 2008
    Is Medtronic's stumble a buying opportunity?
  129. Wyeth's Day In Court

    November 6, 2008
    Wythe and other drug companies are anxiously awaiting the outcome a product labeling liability case before the U.S. Supreme ...
  130. Sigma-Aldrich's New Tech Proves Recession-Proof

    October 29, 2008
    Sigma-Aldrich's Q3 earnings were steady, and with downside protection a major theme in the markets these days, it's hard ...
  131. Take A Pass On Boston Scientific

    October 28, 2008
    With so many high-quality medical device stocks trading lower, the argument for Boston Scientific is less compelling.
  132. Who's Really Winning The Heart-Stent Race?

    May 14, 2008
    All the stent makers claim they're the sole industry leader. We help cut through the clutter.
  133. Steady Heart Required (EVVV, SPNC, POSS)

    August 20, 2007
    We examine a trio of small-cap firms who focus on cardiovascular problems. Is it worth investing in potential?
  134. Booster Shot Needed (BSX, BDX)

    July 6, 2007
    A look at two medical technology companies who make "must have" products, yet struggle to find success.
  135. As Good As New (BDX, BSX, ZMH)

    May 11, 2007
    A look at several companies poised to meet the healthcare needs of the aging baby-boomer generation
  136. Panic Begets Opportunity (JNJ)

    March 1, 2007
    In the wake of the recent market sell-off, shares of the always stable JNJ appear to be a good value play.
  137. Winners and Losers - November 6th - November 10th (KOSP, ADLR, ...

    November 10, 2006
    A look at some of the market's winners and losers for the week of November 6th.
  138. Boston Scientific Shaken, But Not Stirred (BSX)

    November 8, 2006
    Boston Scientific looks poised for higher per share valuations in the future.
Investing News
  1. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  2. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  3. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  4. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
  5. Can Paying Off Your Mortgage Early Hurt Your Net Worth?

    Saving your money and making double or even triple payments on a mortgage may sound productive, ...
  6. What $250,000 Will Buy In The Phoenix Real Estate Market

    The number of real estate listings in the Phoenix-Mesa market has increased more than 45% since ...
Trading Center